INHALED IMATINIB FOR PULMONARY ARTERIAL HYPERTENSION CLINICAL TRIAL: DESIGN OF THE IMPACT PHASE 2B/3 STUDY DESIGN

被引：1
|
作者：
Gillies, Hunter
Chakinala, Murali M.
Dake, Ben
Feldman, Jeremy P.
Hoeper, Marius M.
Humbert, Marc
Jing, Zhi-Cheng
Langley, Jonathan
McLaughlin, Vallerie
Niven, Ralph
Rosenkranz, Stephan H.
Zhang, Xiaosha
Hill, Nicholas S.
机构：
来源：
CHEST | 2022年 / 162卷 / 04期
关键词：
D O I：
10.1016/j.chest.2022.08.1923
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：2325A / 2329A
页数：5
相关论文
共 50 条
  • [41] Transform-UK: A Phase 2 Trial of Tocilizumab in Pulmonary Arterial Hypertension
    Toshner, M.
    Church, A.
    Harlow, L.
    Coghlan, G.
    Gibbs, S.
    Gor, D.
    Hernandez-Sanchez, J.
    Kiely, D.
    Knightbridge, E.
    Suntharalingam, J.
    Wilkins, M.
    Wort, J.
    Gaine, S. P.
    Morrell, N. W.
    Corris, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [42] Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial
    Lewis, Roger J.
    Angus, Derek C.
    Laterre, Pierre-Francois
    Kjolbye, Anne Louise
    van der Meulen, Egbert
    Blemings, Allan
    Graves, Todd
    Russell, James A.
    Carlsen, Jan E.
    Jacobsen, Karsten
    Yealy, Donald M.
    Opal, Steven M.
    Windelov, Nis A.
    Francois, Bruno
    Perner, Anders
    Pickkers, Peter
    Berry, Scott M.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (02) : 250 - 257
  • [43] Safety Update on Dapagliflozin (DAPA) across the Phase 2b/3 Clinical Trial Program
    Jabbour, Serge A.
    Seufert, Jochen
    Scheen, Andre J.
    Bailey, Clifford J.
    Karup, Cathrina
    Langkilde, Anna Maria
    DIABETES, 2017, 66 : A338 - A339
  • [44] Positive Phase 2b Clinical Trial of Psoriasis Drug Apremilast
    不详
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (03) : 283 - 283
  • [45] Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)
    Martinez, Fernando J.
    Wijsenbeek, Marlies S.
    Raghu, Ganesh
    Flaherty, Kevin R.
    Maher, Toby M.
    Wuyts, Wim A.
    Kreuter, Michael
    Kolb, Martin
    Chambers, Daniel C.
    Fogarty, Charles
    Mogulkoc, Nesrin
    Tutuncu, Ahmet S.
    Richeldi, Luca
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (09) : 1084 - 1092
  • [46] A Pharmacokinetic/Pharmacodynamic Based Rationale for Dose Selection of the TPH Inhibitor Rodatristat Ethyl in ELEVATE-2-a Phase 2b Study in Pulmonary Arterial Hypertension
    Johnson, B.
    Palacios, M.
    Zhou, J.
    Schmith, V. D.
    Wring, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [47] Intrathecally administered recombinant human arylsulfatase A in patients with late-infantile metachromatic leukodystrophy: Phase 2b clinical trial design
    Whiteman, David
    Vanderver, Adeline
    Kraegeloh-Mann, Ingeborg
    Gray, Jill
    Wu, James
    Wasilewski, Margaret
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S152 - S152
  • [48] Clinical Worsening Of Pulmonary Arterial Hypertension: The COMPASS-3 Study
    Benza, R. L.
    Gupta, H.
    Soto, F.
    Park, M. H.
    Torres, F.
    Frey, N.
    Murali, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [49] Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design
    Cracowski, JL
    Yaici, A
    Sitbon, O
    Reynaud-Gaubert, M
    Renversez, JC
    Pison, C
    Faure, P
    Cracowski, C
    Chouri, N
    Chaouat, A
    Chabot, F
    Schwedhelm, E
    Maas, R
    Degano, B
    Mornex, JF
    Humbert, M
    REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (06) : 1137 - 1143
  • [50] A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design
    S.M. Gadgeel
    R.R. Boinpally
    L.K. Heilbrun
    A. Wozniak
    V. Jain
    B. Redman
    M. Zalupski
    R. Wiegand
    R. Parchment
    P.M. LoRusso
    Investigational New Drugs, 2003, 21 : 63 - 74
12345